Not Specified
Schizophrenia
Key Facts
About Minerva Neurosciences
Minerva Neurosciences is dedicated to transforming the lives of patients suffering from debilitating central nervous system diseases through the development of novel therapeutic solutions. The company's core expertise lies in clinical development, with a patient-focused approach to designing innovative trials. Its pipeline targets significant unmet medical needs in schizophrenia and Parkinson's disease, aiming to deliver meaningful clinical improvements. As a public company, Minerva continues to advance its candidates through clinical development.
View full company profileAbout Minerva Neurosciences
Minerva Neurosciences is dedicated to transforming the lives of patients suffering from debilitating central nervous system diseases through the development of novel therapeutic solutions. The company's core expertise lies in clinical development, with a patient-focused approach to designing innovative trials. Its pipeline targets significant unmet medical needs in schizophrenia and Parkinson's disease, aiming to deliver meaningful clinical improvements. As a public company, Minerva continues to advance its candidates through clinical development.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |